Reference Pricing And Generic Entry Of Medicinal Products From The Therapeutic Group Erythropoetins

Jivko Kolev; Nadia Kirova; Evgeni Grigorov

doi:10.14748/.v4i1.5510

Reference Pricing And Generic Entry Of Medicinal Products From The Therapeutic Group Erythropoetins

Jivko Kolev, Nadia Kirova, Evgeni Grigorov

Abstract

The study shows that the impact on sales value of the erythropoietin therapeutic group is similar to other 100% reimbursed medicinal products. The only difference is for decrease in the value of erythropoietins are 16.25%. The weaker impact of drug policies in the biosimilar group is most likely due to the delayed penetration of this type of medication requiring specific trials demonstrating bioequivalence and, most likely, less opportunity for alternatives to drug administration. The average decrease in the price of medicinal products from the erythropoietin group for the period 2011-2017 was 29.4% (-50.68% ÷ + 69.1%) from 40,12 BGN to 28,35 BGN.

Keywords

reference pricing, generic entry, medicinal product, erythropoietin

Full Text

References

Стоименова А, Цачев Х. Биотехнологичните лекарства от лабораторията до пациента. София: Унив. изд. “Св. Климент Охридски”; 2016.

Brooks G. Biotechnology in Healthcare: An Introduction to Biopharmaceuticals. Pharm Press. 1998;30(15):20–3.

Buchholz K CJ. Concepts in biotechnology—history, science and business. Wiley-VCH, Weinheim. 2010;

Buchholz K. Science—or not? The status and dynamics of biotechnology. Biotechnol J. 2007;2(9):1154–1168.

Веков Т. Лекарствена политика, реимбурсация и ценообразуване. София: Български кардиологичен институт; 2011. 268 с.

Genazzani AA, Biggio G, Caputi AP, Del Tacca M, Drago F, Fantozzi R, et al. Biosimilar Drugs. BioDrugs [Internet]. 2007;21(6):351–6. Available from: https://doi.org/10.2165/00063030-200721060-00003

Петрова Г, Петкова В, Гетов И, Стоименова А, Савова А, Манова М, и кол. Социална фармация и фармацевтично законодателство. 2017. 360 с.

http://www.emea.eu.int. European Medicines Agency.

Ledford H. Biosimilar’ drugs poised to penetrate market. Nature. 2010;468:18–9.

Schiestl M, Zabransky M, Sörgel F. Ten years of biosimilars in Europe: development and evolution of the regulatory pathways. Drug Des Devel Ther. Dove Medical Press; 2017 May 16;11:1509–15.

Aggarwal S. What’s fueling the biotech engine? Nat Biotechnol. 2007;25(10):1097–1104.

Chance R, Glazer N, Wishner K. Biopharmaceuticals, an Industrial Perspective. In: Kluwer Academic Publishers, Dordrecht, The Netherlands. 1998. p. 149–172.

DOI: http://dx.doi.org/10.14748/.v4i1.5510